American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 826-829 , November 2008

Ferumoxytol as a New, Safer, Easier-to-Administer Intravenous Iron: Yes or No?

  • Michael Auerbach, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Michael Auerbach, MD, 9110 Philadelphia Rd, #314, Baltimore, MD 21237

References 

  1. Watson Pharmaceuticals, Inc: INFeD Prescribing Information. Morristown, NJ: Watson Pharmaceuticals, Inc; 2006;
  2. American Regent, Inc: DexFerrum Prescribing Information. Shirley, NY: American Regent, Inc; 2001;
  3. Watson Pharmaceuticals, Inc: Ferrlecit Prescribing Information. Morristown, NJ: Watson Pharmaceuticals, Inc; 2004;
  4. American Regent, Inc: Venofer Prescribing Information. Shirley, NY: American Regent, Inc; 2005;
  5. Landry R, Jacobs PM, Davis R, et al. Pharmacokinetic study of Ferumoxytol: A new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol. 2005;25:400–410
  6. Manley HJ, McClaran ML. Determination of VIT 45 (IND#63,243 – American Regent) removal by closed loop in vitro hemodialysis system. Int J Artif Organs. 2006;29:1062–1066
  7. FDA Advisory Committee Briefing Document, Drug Safety and Risk Management Committee, February 1, 2008. http://www.fda.gov/ohrms/dockets/AC/08/briefing/2008-4337b1-01-FDA.pdfAccessed August 27, 2008
  8. Singh A, Patel T, Hertel J, et al. Safety of Ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52:907–915
  9. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378–382
  10. Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: a wolf in sheep's clothing?. J Am Soc Nephrol. 2008;19:833–834
  11. Zager RA, Johnson ACM, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002;40:90–103
  12. Zager RA, Johnson ACM, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 2004;66:144–156
  13. Agarwal RA, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004;65:2279–2289
  14. Leehey DJ, Palubiak DJ, Chebrolu S, Agarwal R. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol Dial Transplant. 2005;20:135–140
  15. Agarwal R, Rizkala AR, Kaskas MO, Minasian R, Trout JR. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int. 2007;72:638–642
  16. Agarwal R. On the nature of proteinuria with acute renal injury in patients with chronic kidney disease. Am J Physiol Renal Physiol. 2005;288:F265–F271
  17. Pai AB, Boyd AV, McQuade CR, et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007;27:343–350
  18. Auerbach M, Al Talib KA. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int. 2008;73:528–530
  19. Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med. 2007;357:93–94
  20. Monieum KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients: a comparison of preparations. Transfusion Altern Transfusion Med. 2007;9:37–42
  21. Sav T, Tokgoz B, Sipahioglu MH. Is there a difference between allergic potencies of the iron sucrose and low molecular weight iron dextran?. Ren Fail. 2007;29:423–426
  22. Fishbane S, Ungureanu VD, Maesake JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996;28:528–534
  23. Asero R, Tedeschi A, Riboldi P, Grafini S, Bonanni E, Cugno M. Coagulation cascade and fibrinolysis in patients with multiple-drug allergy syndrome. Ann Allergy Asthma Immunol. 2008;100:44–48
  24. Coyne DW, Adkinson FN, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients (II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients). Kidney Int. 2003;63:217–224
  25. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;369:1502–1504

PII: S0272-6386(08)01356-5

doi: 10.1053/j.ajkd.2008.09.006

American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 826-829 , November 2008

Article Tools